Introduction {#s1}
============

Pancreatic ductal adenocarcinoma (PDAC), which represents one of the most common gastrointestinal tumors, is the fourth cause of cancer deaths in developed countries ([@B1]). Surgery leads to the best chance of survival with a 5-year overall survival (OS) rate of only 5--7% ([@B2]). Compared with PDAC of the head of the pancreas, the discrepancies of ontogeny would lead to significant differences in cell composition, blood supply, lymphatic and venous backflow in PDAC of the body and tail of the pancreas ([@B3]). Moreover, due to the lack of obstructive jaundice, PDAC which occurred at the body and tail has a lower resectable rate and a more dismal prognosis than PDAC of the head ([@B4], [@B5]).

Several independent prognostic factors of PDAC have been identified, such as lymph node (LN) metastasis, tumor size, and resection margin ([@B6], [@B7]). In these studies, the prognostic influence of risk factors on PDAC of the body and tail is only estimated because the reported predictors of prognosis mainly focus on PDAC occurring at the pancreatic head. It is known that the differences in ontogeny lead to significant differences in clinical characteristics between tumors occurred at the head or the body/tail ([@B8]). However, the 8th edition of the tumor-node-metastasis (TNM) staging system of the American Joint Commission on Cancer (AJCC), ([@B9]) which is commonly used to stage diseases, takes only common predictive factors into account and does not incorporate the tumor site. Furthermore, the 8th edition of the TNM is still cumbersome and not specifically designed to predict prognosis. The TNM staging system algorithm, which uses risk factors to make clinical decisions, needs to be validated. The lack of an accurate and reliable staging system for PDAC of the body and tail makes it difficult and challenging for doctors to appropriately identify patients at risk of long-term survival. Therefore, it is necessary to develop a technically feasible and an easily accessible clinical staging system to stratify the prognosis of patients with PDAC of the body and tail when surgery is urgently required.

Nomograms, which have been adopted in various cancers ([@B10]--[@B13]) and have shown favorable results, compared with traditional TNM staging systems, ([@B14]) are simple graphical depictions of the predictive model and are used to provide the probabilities of outcomes for individual patient ([@B15]). However, few studies have reported specific nomograms for patients with PDAC of the body and tail after surgery. The purpose of this analysis was to develop a clinically useful nomogram which could be used to predict the prognosis of patients with PDAC of the body and tail after surgery.

Materials and Methods {#s2}
=====================

Study Design
------------

In this retrospective study, according to the inclusion and exclusion criteria, suitable patients were selected and clinicopathological variables of these patients were retrospectively reviewed. Extensive evaluation of concerning risk factors were conducted using a univariate analysis for all included variables and a multivariate analysis was adopted to select the independent risk factors. A nomogram was built based on these independent risk factors and validated in both training and external validation cohorts. The predictive power of the established nomogram was also compared with that of the 7th and 8th editions of TNM stage systems. This study was approved by the Institutional Review Board (IRB) of the Sun Yat-sen University Cancer Center. Each individual participant from the SYSUCC database provided informed written consent. All procedures performed in studies involving human participants were in accordance with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.

Patients
--------

The Surveillance, Epidemiology, and End Results (SEER) program maintains the largest clinical dataset in the United States and provides data on cancer incidence and survival. For this research, the training cohort of patients with PDAC of the body and tail were obtained from the SEER database (2004--2015). The International Classification of Diseases for Oncology, Third Edition (ICD-O-3), histology code 8140/3 and site codes C25.1 and C25.2, were followed in the SEER database using SEER^\*^Stat software version 8.3.4. The second cohort of patients was obtained from the SYSUCC (2009--2017), which was used as an external validation cohort. The inclusion criteria were as follows: (1) pathologically confirmed pancreatic adenocarcinoma and radiologically confirmed PDAC of the body and tail; (2) radical surgical resection. The following exclusion criteria were adopted: (1) second primary cancer; (2) distant metastases; (3) other treatments only, including chemotherapy or radiotherapy; and (4) missing or incomplete information. The information of TNM system was adopted in this study, which was in accordance with previous studies ([@B16], [@B17]).

Data Collection
---------------

Pathological and clinical variables, such as age at diagnosis, gender, tumor size, tumor differentiation, TNM stage, chemotherapy, radiotherapy, and follow-up information, were extracted from the SEER and SYSUCC databases. Sixty was used as the cutoff value of age in this study. The time-dependent receiver operating characteristic (ROC) curve analysis was used to determine the optimal cutoff value for lymph node ratio (LNR), which was defined as the same as previous studies ([@B18]). OS was calculated from the date of surgery to the date of death or last follow-up.

Statistical Analysis
--------------------

The chi-square test and Fisher\'s exact test were used to compare categorical data, which are shown as frequencies and proportions. Variables that were significantly associated with OS were analyzed in the multivariate analysis using the Cox regression model to determine the independent predictive factors, along with the corresponding 95% confidence interval (CI). Survival differences were compared with log-rank test. The nomogram was developed according to previous protocols ([@B18]--[@B20]) and the area under the ROC curve (AUC) was used to evaluate and compare the precision of predicting 1-, 2-, and 3-year survival with the nomogram. All statistical analyses were performed using R version 3.4.2 software (The R Foundation for Statistical Computing, Vienna, Austria. <http://www.r-project.org>). A two-tailed *P*-value was considered statistically significant if \< 0.05.

Results {#s3}
=======

Patient Characteristics
-----------------------

The work flow of the current study is shown in [Figure 1](#F1){ref-type="fig"}. The data of a total of 483 eligible patients with PDAC of the body and tail after surgery were obtained from the SEER database. There were 213 patients with PDAC of the body, and the other 270 patients had PDAC of the tail. A summary of baseline characteristics of the patients is shown in [Table 1](#T1){ref-type="table"}. The median age of patients in the SEER database was 65 years (range: 32--91 years). Of these patients, 238 (49.3%) were male. A tumor size larger than 4 cm (222; 46.0%) was the most common size. Moderately differentiated tumors (242; 50.1%) were most common, followed by poorly differentiated (194; 40.2%) and well-differentiated tumors (47; 9.7%). A total of 252 (52.2%) patients had LN metastasis. Most patients (168; 34.8%) were categorized as TNM stage III, 29.6% (143) were stage IIB, 12.0% (58) were stage IIA, and 23.6% (114) were stage I. In addition, the proportions of patients with LN metastasis and higher LNR values were higher in patients with PDAC of the tail. Other than these two variables, the other characteristics, including age, gender, race, tumor size, tumor differentiation, and TNM stage (8th edition), were comparable. LNR, with a cutoff value of 0.118, showed the greatest predictive power and was used to analyze survival in this study ([Supplementary Figure 1](#SM1){ref-type="supplementary-material"}). A total of 230 (47.6%) patients had received chemotherapy while 141 (29.2%) patients received radiotherapy in this study.

![The flow diagram of the selection process for the study cohort.](fonc-10-00590-g0001){#F1}

###### 

Characteristics and overall survival of patients with pancreatic adenocarcinoma of the body and tail.

  **Characteristics**           **SEER cohort**   **SYSUCC cohort**                                                      
  ----------------------------- ----------------- ------------------- ------- ----- ----- ------- ---- ------- ---- ---- -------
  Total                                           483                 100.0   213   270           94   100.0   41   53   
  Age                           \<60 years        318                 65.8    137   181   0.563   72   76.6    29   43   0.326
                                ≥ 60 years        165                 34.2    76    89            22   23.4    12   10   
  Gender                        Male              238                 49.3    106   132   0.855   52   55.3    20   32   0.300
                                Female            245                 50.7    107   138           42   44.7    21   21   
  Race                          White             378                 78.3    177   201   0.052                          NA
                                Black             57                  11.8    17    40                                   
                                Asian             48                  9.9     20    28                                   
  Tumor size                    ≤ 2 cm            76                  15.7    37    39    0.107   13   13.8    3    10   0.274
                                2 \~ 4 cm         185                 38.3    90    95            28   29.8    13   15   
                                \> 4 cm           222                 46.0    87    135           53   56.4    25   28   
  Tumor differentiation         Well              47                  9.7     18    29    0.510   6    6.4     3    3    0.948
                                Moderately        242                 50.1    98    144           81   86.2    35   46   
                                Poorly            194                 40.2    89    105           7    7.4     3    4    
  LN metastasis (7th edition)   Absent            231                 47.8    120   111   0.002   86   91.4    37   49   0.725
                                Present           252                 52.2    99    159           8    8.6     4    4    
  LN metastasis (8th edition)   Absent            231                 47.8    120   111   0.006   86   91.4    37   49   0.930
                                1 \~ 3 LNs        180                 37.3    65    115           4    4.3     2    2    
                                ≥ 4 LNs           72                  14.9    28    44            4    4.3     2    2    
  LNR                           \<0.118           323                 66.9    154   169   0.039   88   93.6    37   51   0.398
                                ≥ 0.118           160                 33.1    56    104           6    6.4     4    2    
  Chemotherapy                  No                253                 52.4    113   140   0.854   32   34.0    18   14   0.084
                                Yes               230                 47.6    100   130           62   66.0    23   39   
  Radiotherapy                  No                342                 70.8    148   194   0.615   66   70.2    31   35   0.368
                                Yes               141                 29.2    65    76            28   29.8    10   18   
  TNM 8th stage                 IA                46                  9.5     25    21    0.067   11   11.6    1    10   0.191
                                IB                68                  14.1    31    37            24   25.5    12   12   
                                IIA               58                  12.0    31    27            51   54.3    24   27   
                                IIB               143                 29.6    61    82            4    4.3     2    2    
                                III               168                 34.8    73    95            4    4.3     2    2    

*LN, lymph node; LNR, lymph node ratio; TNM, tumor-node-metastasis*.

Additionally, 94 patients from the SYSUCC cohort were included. Similar to patients from the SEER cohort, most patients were younger than 60 years old. Cases that had a moderately-differentiated tumor or absence of LN metastasis, made up most of the patients and more than half of patients had tumors that were larger than 4 cm. A total of 62 (66.0%) patients had received chemotherapy while 28 (29.8%) patients received radiotherapy in this study. The two groups of patients had substantially balanced clinical and pathological variables.

OS Analysis
-----------

For patients in the SEER cohort, the median OS was 20 months, and the 1-, 2-, and 3-year OS rates were 68.4, 45.7, and 32.8%, respectively. Patients were stratified by characteristics for the OS analyses. The differences in OS rates were all significant, except upon stratification by gender and race ([Figure 2](#F2){ref-type="fig"} and [Table 1](#T1){ref-type="table"}). As shown in [Table 2](#T2){ref-type="table"}, gender, race, and tumor site were not risk factors for OS (*p* \> 0.050), while age, tumor size and differentiation, LN metastasis (7th edition), LN metastasis (8th edition), LNR, chemotherapy, and radiotherapy were significantly associated with OS in the univariate analysis. The multivariate analysis, which incorporated these variables, indicated that tumor size, tumor differentiation and LNR sustained their significance in terms of OS after adjusting for covariates. In addition, older patients had a trend for poor OS compared with younger patients, while the multivariate analysis failed to show age as a significant predictor of OS.

![Kaplan-Meier OS curves stratified by patient characteristics: **(A)** Age; **(B)** Gender; **(C)** Tumor size; **(D)** Tumor differentiation; **(E)** LN metastasis (7th edition); **(F)** LN metastasis (8th edition); **(G)** LNR. OS, overall survival; LN, lymph node; LNR, lymph node ratio; TNM, Tumor-Node-Metastasis.](fonc-10-00590-g0002){#F2}

###### 

Univariate and multivariate analyses of survival in patients with pancreatic adenocarcinoma of the body and tail.

  **Characteristics**           **Overall survival**                                                                      
  ----------------------------- --------------------------------- ------- -------------- --------- ------- -------------- ---------
  Age (years)                   \<60/≥ 60                         1.361   1.049--1.765   0.020     1.222   0.901--1.658   0.197
  Gender                        Male/Female                       0.858   0.667--1.104   0.233                            NI
  Race                          White/Black/Asian                 1.078   0.894--1.298   0.432                            NI
  Tumor site                    Body / Tail                       1.160   0.900--1.495   0.252                            NI
  Tumor size (cm)               ≤ 2/2 \~ 4/\> 4                   1.648   1.366--1.988   \<0.001   1.539   1.225--1.934   \<0.001
  Tumor differentiation         Well/Moderately/Poorly            1.492   1.190--1.870   0.001     1.283   1.005--1.637   0.045
  LN metastasis (7th edition)   Absent/Present                    1.760   1.359--2.278   \<0.001   1.093   0.625--1.911   0.756
  LN metastasis (8th edition)   Absent/1 \~ 3/≥ 4 LN metastasis   1.564   1.308--1.871   \<0.001   0.936   0.625--1.403   0.749
  LNR                           \<0.119/≥ 0.119                   2.111   1.604--2.779   \<0.001   1.771   1.113--2.818   0.016
  Chemotherapy                  No/Yes                            2.015   1.511--2.889   \<0.001   1.585   1.021--2.774   0.001
  Radiotherapy                  No/Yes                            1.178   0.88--2.114    0.184                            NI

*HR, hazard ratio; CI, confidence interval; NI, not included*.

Construction of the Nomogram
----------------------------

A nomogram was built using the abovementioned variables *via* the Cox proportional hazards model. As shown in [Figure 3](#F3){ref-type="fig"}, the nomogram predicted the OS probabilities of 1--3 years for patients with PDAC of the body and tail after surgery. For patients from the SEER cohort, the bias-corrected concordance indexes (C-indexes) of the nomogram were higher than those of the 7th edition of the TNM staging system \[0.775 (95% CI, 0.731--0.819) vs. 0.617 (95% CI, 0.575--0.659), *P* = 0.006\] and the 8th edition of the TNM staging system \[0.775 (95% CI, 0.731--0.819) vs. 0.632 (95% CI, 0.588--0.676), *P* = 0.033\]. Elevated C-indexes of the established nomogram were also observed in patients from the SYSUCC cohort, compared with the TNM staging system ([Table 3](#T3){ref-type="table"}). Excellent agreement between the predictive and the actual observed 1-, 2-, and 3-year OS survival was shown by calibration plots ([Figure 4](#F4){ref-type="fig"}). The discriminatory power of the newly developed nomogram was superior to that of the TNM staging system in this study.

![Nomograms predicting 1-, 2-, and 3-year OS of patients with pancreatic adenocarcinoma of the body and tail after surgery. OS, overall survival; LNR, lymph node ratio.](fonc-10-00590-g0003){#F3}

###### 

Comparison of the C-index and AUC values between nomograms and TNM stages.

  **Patients**                    **Overall survival**                           
  --------------- --------------- ---------------------- ------- ------- ------- -------
  SEER cohort     Nomogram        0.775 (0.731--0.819)   0.661   0.733   0.721   
                  7th TNM stage   0.617 (0.575--0.659)   0.639   0.691   0.667   0.006
                  8th TNM stage   0.632 (0.588--0.676)   0.651   0.702   0.690   0.033
  SYSUCC cohort   Nomogram        0.747 (0.685--0.809)   0.636   0.682   0.644   
                  7th TNM stage   0.602 (0.553--0.651)   0.620   0.646   0.589   0.008
                  8th TNM stage   0.607 (0.551--0.663)   0.620   0.652   0.572   0.018

*C-index, concordance index; AUC, area under receiver operating characteristic curves*.

![Calibration plots of the nomogram for 1-, 2-, and 3-year OS prediction in the training cohort **(A--C)** and validation cohort **(D--F)**. X-axis represents the nomogram-predicted probability of survival; Y-axis represents the actual OS probability. A perfectly accurate nomogram prediction model would result in a plot that the observed and predicted probabilities for given groups fall along the 45-degree line. Dots with bars represent nomogram-predicted probabilities along with 95% confidence interval.](fonc-10-00590-g0004){#F4}

Comparison of AUC Values of the Nomogram and TNM Staging System
---------------------------------------------------------------

The ROC curves were used to compare the precision of the 1-, 2-, and 3-year OS predictions. For the training cohort from the SEER database, the AUC values of the nomogram that predicted 1-, 2-, and 3-year OS rates were 0.661, 0.733, and 0.721, respectively, whereas the values of the TNM staging system were 0.639, 0.691, and 0.667 (7th edition) and 0.651, 0.702, and 0.690 (8th edition), respectively. In patients from the external validation cohort, the established nomogram also displayed significantly higher values of AUC than those of the TNM stage system ([Table 3](#T3){ref-type="table"}). As shown in [Figure 5](#F5){ref-type="fig"}, the nomogram exhibited superior predictive ability to that of the TNM staging system.

![Comparison of the ROC curves of the nomogram and the TNM stage systems for 1-, 2-, and 3-year OS prediction in the training cohort **(A--C)** and validation cohort **(D--F)**.](fonc-10-00590-g0005){#F5}

Discussion {#s4}
==========

The differences in characteristics and prognoses between PDAC of the head and those of the body and tail urged us to pursue a specific staging system for pancreatic body and tail cancer, even though previous studies have compared the predictive power of nomograms in terms of PDAC, ([@B21], [@B22]) which were primarily focused on pancreatic head cancer. In the present study, using a relatively large cohort, a novel nomogram was established to predict OS rates in patients with PDAC of the body and tail in this study. The well-established nomogram seemed to be more significantly predictive than the TNM staging system.

The assessment and prediction of prognosis by the established nomogram differed from those made by current TNM staging systems. Tumor differentiation was proven to be an independent prognostic factor for predicting OS in these patients and was incorporated into the nomogram. Previous studies have confirmed the prognostic significance of tumor differentiation in PDAC, ([@B23], [@B24]) and this was consistent with our results. As a pathological variable which was independent of other variables, including tumor size and LN metastasis, may provide additive prognostic power in survival estimation. According to the nomogram, different levels of tumor differentiation meant different points and different OS rates in patients, even if they had tumors with the same TNM stage. The additive predictive power provided by these variables surely contributed to the superior power of the nomogram for predicting OS, compared with the 7th and 8th editions of the TNM staging system.

Moreover, patients stratified by age had significantly different OS rates in this study. Age alone appeared to affect survival rates after surgical resection in patients with pancreatic cancer ([@B25]). Age-related comorbid conditions or complications could possibly contribute to mortality in older patients. Age failed to be classified as an independent prognostic factor, although significant differences in OS were observed among patients stratified by age in this study. It is possible that an even larger cohort will confirm the prognostic significance of age in survival analyses. It was expected that age would have an important role in predicting survival ([@B26]). Thus, age was added to the nomogram established in this study and was capable of improving the prognostic efficiency.

Currently, LN involvement remains one of the most important predictors of survival in patients with PDAC ([@B27], [@B28]). An interesting phenomenon was shown in this study: the classic "N" stages of both the 7th and 8th editions of the TNM staging system failed to exhibit independent predictive significance, whereas LNR was proven to be an independent predictive factor in the OS analysis; these results were similar to those of other studies ([@B29], [@B30]). The time-dependent ROC curve analysis was used to determine the optimal cutoff value for LNR. Similar to the results of Pan et al. ([@B31]) this method, which was used in many similar reports, ([@B32]--[@B34]) decided the cutoff value of LNR with more predictive power due to the consideration of the survival time in evaluating the values. As a significant modifier of the effects of LN status, ([@B35]) LNR showed the potential for LN metastasis, which was similar with previous studies ([@B36]). In this sense, LNR was established as a better predictor of OS than the status of LN metastasis, ([@B37]) and a higher LNR value was strongly associated with poor distant metastasis-free survival ([@B38]).

In addition to the abovementioned factors, tumor size and chemotherapy were also identified as significant predictors of survival in these patients. Consistent with many previous reports, ([@B21], [@B39]) our results confirmed the significant predictive roles of these two factors in predicting survival in patients with PDAC. Moreover, previous studies had found that status of resection margin of surgery for PDAC of the body and tail had great impact on survival. For a more accurate estimation of survival, all patients included in this study had received radical resection and the impact of resection margin on survival was minimal in this study. Thus, in the nomogram model, each factor from the multivariate Cox proportional hazard regression model was ascribed a weighted point total that implied a survival prognosis. The established nomogram makes it easier for physicians to assess a variety of parameters with more objectivity and precision and to distinguish subgroups with different prognoses among patients with PDAC of the body and tail after radical resection. There are two major applications of the nomogram. First, as a quantitative scoring system, the nomogram can be used to predict survival of patients with PDAC of the body and tail. Second, for patients with high scores calculated by the established nomogram, close follow-up or appropriate treatment may be required. The combination of the main elements from the TNM staging system and other tumor-associated indices, including age, tumor differentiation and LNR, would surely contribute to a better discriminatory power of the nomogram in predicting survival, compared with the TNM staging system. The established nomogram can be used as a practical tool to predict clinical outcomes, and it has potential use in decision-making regarding subsequent treatment of patients with PDAC of the body and tail after surgery.

There are limitations in the present study that should be addressed. First, this was a retrospective study that relied on the SEER database. Some of the potential predictors of survival, such as perineural invasion, lymphovascular invasion, and portal vein involvement, could not be included in the nomogram. Second, although good fitness was demonstrated for the validation in the present study, we should recognize that bootstrapping is only helpful to reduce the overfit bias of the nomogram. More validations using large and independent cohorts are necessary for the present nomogram.

In this study, we analyzed the prognostic data of PDAC of the body and tail using the SEER database. A nomogram for the estimation of 1-, 2-, and 3-year OS was established based on a large study cohort for the first time. The present nomogram can predict the prognosis of patients with PDAC of the body and tail after surgery with considerable accuracy and can help doctors provide highly tailored patient management in the future.
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The ROC curve of survival based on the changes of LNR value.
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Click here for additional data file.
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